Cargando…
Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19
Autores principales: | Destras, Grégory, Assaad, Souad, Bal, Antonin, Bouscambert-Duchamp, Maude, Avrillon, Virginie, Simon, Bruno, Valette, Martine, Blay, Jean-Yves, Lina, Bruno, Frobert, Emilie, Josset, Laurence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318407/ https://www.ncbi.nlm.nih.gov/pubmed/34341781 http://dx.doi.org/10.1016/S2666-5247(21)00189-0 |
Ejemplares similares
-
SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant
por: Sentis, Célia, et al.
Publicado: (2022) -
Sotrovimab drives SARS-CoV-2 omicron variant evolution in immunocompromised patients
por: Destras, Grégory, et al.
Publicado: (2022) -
The NS Segment of H1N1pdm09 Enhances H5N1 Pathogenicity in a Mouse Model of Influenza Virus Infections
por: Ferraris, Olivier, et al.
Publicado: (2018) -
Characterization of SARS-CoV-2 ORF6 deletion variants detected in a nosocomial cluster during routine genomic surveillance, Lyon, France
por: Quéromès, Grégory, et al.
Publicado: (2021) -
Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: The example of SARS‐CoV‐2 and monkeypox virus
por: Quéromès, Grégory, et al.
Publicado: (2022)